Robin M Robinson

US Patent:

6458562, Oct 1, 2002

Filed:

Feb 22, 2000

Appl. No.:

09/402776

Inventors:

Suzanne U. Emerson - Rockville MD
Robert H. Purcell - Boyds MD
Sergei A. Tsarev - Rockville MD
Robin A. Robinson - Dickerson MD

Assignee:

The United States of America as represented by the Secretary of Health and Human Services - Washington DC
Novavax, Inc. - Columbia MD

International Classification:

C12N 1551

US Classification:

435 693, 4353201, 530350

Abstract:

The invention relates to the expression of open reading frame 2 (ORF-2) proteins of a strain of hepatitis E virus from Pakistan (SAR-55) in a eukaryotic expression system. The expressed proteins can serve as an antigen in diagnostic immunoassays and/or as an immunogen or vaccine to protect against infection by hepatitis E.

US Patent:

7041500, May 9, 2006

Filed:

Feb 14, 2003

Appl. No.:

10/367095

Inventors:

Robin A. Robinson - Dickerson MD, US

Assignee:

Novavax, Inc. - Malvern PA

International Classification:

C12N 5/16

US Classification:

435348, 4352351

Abstract:

An insect cell line capable of growth in serum-free media and secretion of high levels of recombinant proteins, including virus-like particles, upon infection with recombinant baculoviruses, is provided. Methods involving clonal selection processes, serum-weaning and recombinant protein secretion selection are used to create the insect lines of the invention. This cell line supports replication of baculoviruses, serves as host substrate for baculovirus plaque assays, provides a source of insect proteins, acts as a depot for cell transfection to produce recombinant baculoviruses, and express viral recombinant proteins. Extracellular and intracellular viral recombinant proteins and virus-like particles expressed from this cell line are useful as pharmaceutical compositions, vaccines, or diagnostic reagents.

US Patent:

7763450, Jul 27, 2010

Filed:

Mar 10, 2006

Appl. No.:

11/372466

Inventors:

Robin A. Robinson - Dickerson MD, US
Peter M. Pushko - Frederick MD, US

Assignee:

Novavax, Inc. - Rockville MD

International Classification:

C12N 7/00
C12N 7/04

US Classification:

4352351, 435 691, 435236

Abstract:

Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.

US Patent:

8592197, Nov 26, 2013

Filed:

Jul 11, 2003

Appl. No.:

10/617569

Inventors:

Robin A. Robinson - Dickerson MD, US
Peter M. Pushko - Frederick MD, US

Assignee:

Novavax, Inc. - Rockville MD

International Classification:

C12N 7/04
A61K 39/145

US Classification:

435236, 4352351, 4242041, 4242061, 4242091

Abstract:

Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.

US Patent:

20040063188, Apr 1, 2004

Filed:

Feb 14, 2003

Appl. No.:

10/368046

Inventors:

Robin Robinson - Dickerson MD, US
Mark Thompson - Morgan Hill CA, US

Assignee:

Novavax, Inc. - Columbia MD

International Classification:

C12N007/02

US Classification:

435/239000

Abstract:

Methods for isolation and purification or recombinant gene products are disclosed. In particular, methods for isolation and purification of extracellular and intracellular viral gene products, including virus-like particles, are disclosed herein.

US Patent:

20040121465, Jun 24, 2004

Filed:

Feb 14, 2003

Appl. No.:

10/367367

Inventors:

Robin Robinson - Dickerson MD, US

Assignee:

Novavax, Inc. - Columbia MD

International Classification:

C12N015/86
C12N007/01
C12N005/06

US Classification:

435/456000, 435/235100, 435/348000

Abstract:

Codon optimized polynucleotides for optimal expression of recombinant proteins in eukaryotic cells are provided. The codon optimized polynucleotides encode a viral capsid protein that self assembles into a virus-like particle. The virus-like particle is expressed extracellularly and exhibits conformational antigenic epitopes capable of raising neutralizing antibodies. Pharmaceutical compositions, vaccines, and diagnostic test kits containing the gene products of the codon-optimized polynucleotides are also provided.

US Patent:

20050118191, Jun 2, 2005

Filed:

Aug 13, 2004

Appl. No.:

10/918337

Inventors:

Robin Robinson - Dickerson MD, US
Vittoria Cioce - Kinsington MD, US

International Classification:

A61K039/12
C12P021/04
C12N007/00
C12N005/06

US Classification:

424199100, 435456000, 435235100, 435348000

Abstract:

Chimeric virus-like particles that exhibit conformational antigenic epitopes capable of eliciting neutralizing antibodies are disclosed herein. The chimeric virus-like particles of the invention comprise a recombinant viral capsid protein that encapsulates a recombinant viral protein during self-assembly into a chimeric virus-like particle, wherein the chimeric virus-like particle exhibits confirmational antigenic epitopes capable of eliciting neutralizing antibodies. Pharmaceutical compositions, vaccines, and diagnostic test kits containing the chimeric virus-particles are also provided.

US Patent:

20130039938, Feb 14, 2013

Filed:

Oct 24, 2011

Appl. No.:

13/280043

Inventors:

Gale SMITH - Gaithersburg MD, US
Yingyun Wu - Clarksburg MD, US
Michael Massare - Mt. Airy MD, US
Peter Pushko - Frederick MD, US
Margret Nathan - Montgomery Village MD, US
Thomas Kort - Germantown MD, US
Robin Robinson - Rockville MD, US

Assignee:

NOVAVAX, INC. - Rockville MD

International Classification:

A61K 39/145
C12P 21/02
C12N 9/24
C07K 14/11
A61P 37/04

US Classification:

4241921, 530350, 4242101, 4242091, 435200, 435 691

Abstract:

This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.